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Abstract
Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant
cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia (AML) has in
principle been shown to be a T cell-sensitive disease by the graft-versus-leukemia activity of allogeneic stem cell
transplantation, T cell therapy has so far failed in this setting. This is largely due to the lack of target structures both
sufficiently selective and uniformly expressed on AML, causing unacceptable myeloid cell toxicity. To address this, we
developed a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to AML. This platform
combines synthetic agonistic receptor (SAR) -transduced T cells with AML-targeting tandem single chain variable fragment
(scFv) constructs. Construct exchange allows SAR T cells to be redirected toward alternative targets, a process enabled by
the short half-life and controllability of these antibody fragments. Combining SAR-transduced T cells with the scFv
constructs resulted in selective killing of CD33+ and CD123+ AML cell lines, as well as of patient-derived AML blasts.
Durable responses and persistence of SAR-transduced T cells could also be demonstrated in AML xenograft models.
Together these results warrant further translation of this novel platform for AML treatment.
Keypoints
● Modular platform enabling controlled targeting of AML by SAR-transduced T cells in combination with tandem scFv
constructs.
● Efficient lysis of primary AML blasts in vitro and strong antitumoral effects and T cell persistence in xenograft models.
Introduction
With high relapse rates and few targeted therapeutic
options, there is a need develop novel solutions for the
treatment of acute myeloid leukemia (AML). While stan-
dard therapy (induction chemo- and consolidation therapy)
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does offer a curative first-line therapy to those eligible [1],
leukemic stem cells (LSCs) drive disease relapse in the
majority of responders [2]. In spite of significant advances,
including allogeneic stem cell transplantation and a growing
molecular tailoring of treatment toward driver pathways
such as FLT3 [3], the prognosis of relapsed or refractory
AML remains poor.
Immunotherapy that promotes the killing of tumor cells
by cytotoxic T lymphocytes has entered clinical routine for
hematological malignancies in recent years [4–6]. In acute
lymphocytic leukemia (ALL), bispecific antibodies utilized
for the recruitment of cytotoxic T cells to CD19+ leukemic
cells have been shown to be an effective approach, and are
now part of the standard-of-care [7]. Similarly, anti-CD19
chimeric antigen receptor (CAR) T cell therapy has been
approved in ALL and diffuse large B cell lymphoma based
on unprecedented response rates [8–10]. The cornerstone of
these treatments is a broadly expressed target antigen on
tumor cells that is harnessed to redirect T cells toward the
cancer or leukemic cell [11]. In the case of B cell neoplasia,
the target antigens, CD19 or CD20, are restricted to the B
cell lineage, and the potentially adverse side effect of B cell
depletion has been manageable [11, 12]. In contrast, myeloid
lineage antigens are much less suited as target structures, as
the absence of myeloid cells or of major myeloid lineages is
associated with a high morbidity and mortality rate [13].
Thus, there is a need to render AML targeting by T cells
either modular or conditional to prevent excessive and life-
threatening toxicities whilst enabling clinical activity.
CD33 is an antigen expressed in more than 99% of AML
cases, therefore offering a targeted therapeutic modality with
the potential to induce remission [14, 15]. CD33 is expres-
sed by all early myeloid progenitors (CD34+ CD33+), thus
LSCs that acquired one or more of their transforming events
following commitment to the myeloid compartment are
targetable [16]. Moreover, CD33 has been shown to be
expressed on the majority of CD34+ CD38- LSCs of AML
patient blasts [17, 18]. Along these lines, CD33-targeting
should also be able to eradicate chemo-resistant LSCs.
However, antigen negative escape variants cause disease
relapse in many targeted therapies, emphasizing the need for
sequential or even multiple targeting [19].
The pan-T cell-CD33-targeting bispecific T cell engager
(BiTE) AMG330 recently showed encouraging results in a
phase I trial [14]. In addition, several AML-specific CAR
T cells are currently in clinical trials (NCT03971799;
NCT04010877; NCT04156256). However, none of these
strategies targeted truly AML-specific antigens but rather
antigens either only expressed on subsets of AML cells or
co-expressed by normal myeloid progenitors [20, 21].
Although potentially effective, all aforementioned T cell
strategies are, once deployed, non-reversible and would
therefore benefit from a capability to control T cell activity.
An alternative approach is to transduce T cells with a
synthetic agonistic receptor (SAR) composed of an inert
extracellular domain (EGFRvIII -referred to as E3) acting as a
unique antigen receptor fused to intracellular T cell-activating
domains that can be specifically activated by an engineered
BiAb [22]. Because SARs have no known natural ligands,
this reduces the likelihood of unforeseeable toxicity. Trig-
gering of SAR by the BiAb is dependent on it binding its
second specificity, i.e., a selected tumor-associated antigen on
the tumor cell. This binding allows for BiAb molecules to
aggregate, enabling crosslinking of the SAR. This activates
the T cells and directs T cell-mediated lysis [22]. This tumor-
killing activity is limited by the supply and half-life of the
BiAb. Notably, SAR T cells, unlike CAR T cells, can be
removed from the circulation if needed, by using FDA-
approved monoclonal antibodies, without having to rely on
the addition of a suicide gene [22]. With these favorable
properties, SAR T cells developed to target AML could
overcome the hurdles of toxicities and escape variants.
To enable better control over T cell activity for AML and
ALL indications, we reasoned that we could replace the
BiAb (IgG) with tandem scFv (taFv) constructs as these
would be more controllable and safer due to their shorter
half-life [23, 24]. Here, to test this, we developed novel taFv
constructs made up of two scFvs linked by a (G4S)4 linker.
These constructs have dual specificities: one to target AML
(via binding CD33 or CD123), and the other to target the
SAR-expressing T cell (via binding E3 – which is the inert
extracellular domain of the T cell-activating SAR).
We could show that T cells expressing the SAR construct
can, in a reversible manner, be selectively activated in the
presence of AML cells (CD33+ or CD123+) and the taFv
molecule. We demonstrate that, unlike a conventional BiTE
(anti-CD33–anti-CD3), which activates pan-T cells, our E3-
specific constructs activate only SAR-transduced T cells –
giving additional control over effector cell modifications,
phenotype and dosage. Importantly, we highlight sub-
stantial activity of the platform in primary AML-blast cul-
tures and in different AML-xenograft models, underpinning
the translational potential of the approach.
Methods
Animal experimentation
4-week-old female NSG mice (NOD.Cg-Prkdcscid
Il2rgtm1WjI/SzJ) were purchased from Charles River
(Sulzfeld, Germany). MV4-11-LUC-GFP and THP-1-LUC-
GFP xenograft models were established by intravenously
injecting 2 ×106 or 106 cells, respectively into the tail vein.
taFv molecules were delivered intraperitoneally as indi-
cated. 107 T cells were given intravenously as indicated. All
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animal experiments were approved by the local regulatory
agency (Regierung von Oberbayern). Prior to treatment
mice were randomized according to tumor burden. End-
points were registered by an observer blinded to the treat-
ment groups as previously defined [25]. More than 15%
weight loss after experiment start or a decrease in general
health condition (decreased mobility, general weakness,
hunched posture or ungroomed hair) are defined as humane
surrogate endpoints for survival and are later referred to as
survival of mice. In vivo imaging approach outlined in
supplementary methods.
Binding studies
Apparent dissociation constants (KD) were measured by
calibrated flow cytometry on a Guava easyCyte 6HT
instrument (Merck Millipore, Burlington, MA, USA) with
3.0 to 3.4 μm Rainbow Calibration particles (BioLegend,
San Diego, CA, USA) as calibration control [26]. After
normalization, data points were fitted to a one-site specific
binding model. Expression and purification of molecules is
outlined in supplementary methods.
Cell lines
PL-21, THP-1, MOLM-13, MV4-11, E.G7-OVA, and SEM
cell lines were purchased from ATCC (USA). The E.G7-
OVA cell line was modified to express full-length human
EGFRvIII (Uniprot Entry P00533 AA 1-29, 298–646),
resulting in E.G7-EGFRvIII cells. Luciferase-eGFP (LUC-
GFP) overexpressing cell lines PL-21-LUC-GFP, THP-1-
LUC-GFP and MV4-11-LUC-GFP were generated according
to previously described protocols [22]. Antigen quantification
of cell lines are summarized in Supplementary Table 1A.
293Vec-Galv and 293Vec-RD114 were a kind gift of Manuel
Caruso, Québec, Canada and have been previously described
[27]. All human cell lines were short tandem repeat profiled in
house to verify their origin. Cells were used for a time period
no longer than two months.
Cytotoxicity assays
T cells were incubated with tumor cell lines and taFvs at
indicated effector-to-target ratios and concentrations. Fol-
lowing a 24 h coculture, the BioGlo Assay (Promega, USA)
system was used according to the manufacturer’s protocol.
Confocal microscopy
Blinded confocal imaging and conjugate quantification were
carried out following the selection of 10 representative areas
of each slide. Cells in or out of conjugate within each area
were quantified and a ratio thereof subsequently determined.
For each conjugate, the position of the microtubule organizing
center (MTOC) was observed, and its polarization to the
immune synapse, or lack thereof, was noted. The ratio of
polarized to nonpolarized MTOCs was used to determine the
ratio of functional synapses out of all conjugates formed.
Flow cytometry
Flow cytometry was carried out according to previously
published protocols [28]. For cell number quantification
CountBright® absolute counting beads (Life Technologies)
were added. Samples were analyzed with flow cytometers
from BD, Canto II and Fortessa (BD Bioscience, Germany)
and a Beckman Coulter CytoFLEX for the long-term cultures.
Surface antigen density of cell lines and constructs was eval-
uated with QIFIKIT (Agilent Dako, Santa Clara, CA, USA).
Flow cytometry data were analyzed with FlowJo
V10.3 software or GuavaSoft, version 3.1.1 (Merck Milli-
pore). Staining approach outlined in supplementary methods.
Generation of T cell activating fusion constructs and
T cell transduction
SAR construct generation was previously described [22].
SAR-transduced T cells will be referred to as SAR T cells.
An anti-CD33–CD28–CD3ζ (anti-CD33 CAR) was gener-
ated with the same humanized scFv against CD33 used for
the taFv construct [29]. Transduction and expansion of
primary human T cells was carried out following a pre-
viously described protocol [25]. Virus production methods
outlined in supplementary methods.
Interferon-γ release assays
Human T cell stimulation assays were set up at indicated
concentrations and effector-to-target ratios. IFN-γ was
quantified by ELISA (BD Bioscience).
Long-term coculture assays
AML blasts were cultivated for 3 days before coculture.
Allogeneic healthy donor T cells were incubated with
patient-derived AML blasts at indicated effector-to-target
ratios and concentrations. Untransduced T cells were used to
control for allogeneic effect. Patient blasts were otherwise
cultured according to the previously described protocol [30].
Patient and healthy donor material
After written informed consent in accordance with the
Declaration of Helsinki and approval by the Institutional
Review Board of the Ludwig-Maximilians-Universitaẗ
(Munich, Germany), peripheral blood (PB) or bone marrow
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(BM) samples were collected from healthy donors and AML
patients. At initial diagnosis or relapse, samples were analyzed
at the Laboratory for Leukemia Diagnostics of the Klinikum
der Universitaẗ München as previously described [31, 32].
Patient characteristics are summarized in Supplementary
Table 2A, B.
Statistical analysis
Statistical evaluation was performed using GraphPad
Prism software V8.3.1 (San Diego, CA, USA). Differ-
ences between experimental conditions were analysed as
described in figure P values < 0.05 were considered to
be significant. Data are shown as mean values SEM of
a minimum of three biological replicates or independent
experiments, as indicated. For in vitro experimentation
with healthy donor or patient samples, no statistical
methods were used to predetermine sample size. These
were chosen based on prior experience with this experi-
mental design and patient sample availability. For in vivo
experimentation sample sizes were used in accordance
with prior experience with the models used.
Results
Tandem scFv-mediated effects on SAR T cell
activation, proliferation and differentiation
Based on our previous results, we hypothesized that
the SAR platform could be developed specifically for
AML targeting and treatment [22]. We began by recom-
binantly generating bispecific anti-E3–anti-CD33 and
anti-E3–anti-CD123 taFv molecules. We envisioned that
these E3-targeting molecules could efficiently and
selectively redirect SAR-expressing T cells to AML
blasts (Fig. 1A).
The E3 SAR could be retrovirally transduced into
human T cells from healthy donors with high efficiencies
(Fig. 1B and Supplementary Table 1B). The novel anti-
E3–anti-CD33 molecule was designed to have a high
affinity for the target cells (CD33 KD= 19.5 nM), and a
lower affinity for the T cells (E3 KD= 235.8 nM) so that
aggregates could form more easily on the target cells. The
binding properties and apparent dissociation constants of
the anti-E3–anti-CD33 molecule to both its targets were
analyzed by flow cytometry (Supplementary Fig. 1A and
2A). Similarly, the anti-E3–anti-CD123 molecule was
designed using the same backbone as the CD33-targeting
one and served as an additional AML-specific targeting
taFv molecule to demonstrate the modularity of the plat-
form (CD123 KD= 32 nM) (Supplementary Fig. 1A and
2A). We additionally generated an anti-E3–anti-CD19
molecule to serve as a non-AML-targeting control con-
struct (CD19 KD = 4.9 nM) (Supplementary Fig. 1A and
2A). The anti-CD3–anti-CD33 control has been pre-
viously characterized [33]. Purified proteins were ana-
lyzed by SDS-PAGE and analytical size exclusion
chromatography and protein stability was assessed by
fluorescence-based thermal shift assay (Supplementary
Fig. 1B to E).
In vitro, taFv-mediated T cell activation is strictly
dependent on antibody aggregation on the target cell and
their presentation to the T cell in a polyvalent form [34]. To
assess this conditional T cell activation upon targeting of
the SAR molecule, we incubated SAR T cells with the anti-
E3–anti-CD33 construct in the absence or presence of three
CD33-expressing AML cell-lines, PL-21, THP-1, and
MV4-11, with untransduced (unt) T cells serving as a
control. Only SAR T cells in the presence of the taFv
construct as well as the target antigen were shown to pro-
duce IFN-γ, whereas unt T cells were not stimulated, even
in the presence of both taFv and target molecules (Fig. 1C).
The anti-E3–anti-CD123 taFv was similarly evaluated,
demonstrating both comparable and conditional T cell
activation (Fig. 1C, D).
Congruently, SAR T cell activation following cocul-
ture with target AML cells resulted in enhanced pro-
liferation of both CD4+ and CD8+ SAR T cells when
compared to other T cell and taFv controls (Fig. 1E).
We further observed upregulation of the T cell activation
marker PD-1 specifically for SAR T cells compared to
the control T cells following coculture with target AML
cells and taFv (Fig. 1F). Following activation in culture,
SAR T cells were also observed to have a mixture of
effector and effector memory phenotypes, similar to the
control T cells (Supplementary Fig. 2B)
SAR T cells form functional immunological synapses
to mediate efficient tumor-cell lysis
CD33-expressing tumor cells were effectively targeted
and lysed by anti-E3–anti-CD33 and anti-E3–anti-
CD123-activated SAR T cells, but not unt T cells
(Fig. 2A and Supplementary Fig. 2C). To dissect the-
mode of action of SAR T cells in these settings, we
analyzed the interface between both cell types. Cell
conjugates and synapses formed between the T cells
and tumor cells were labeled and quantified. SAR T
cell conjugates occurred significantly more frequently
than unt T cell-target cell conjugates (Fig. 2B). To probe
the nature of the immunological synapse (IS), we asses-
sed F-actin and CD11a-LFA-1 accumulation. Strong
accumulation of F-actin is indicative of a functional
immune synapse, which was observed to span the entire
area of the synapse (Fig. 2C). A moderate accumulation
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of the LFA-1 signal was also seen at the IS, although
the signal was also observed across the T cell surface.
IS functionality was judged by the polarization of
the MTOC, or lack-thereof, as well as the organization
pattern of the T cell-associated tyrosine kinase, Lck.
Significantly more SAR T cell-target cell conjugates
had a polarized MTOC compared to unt T cell control
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was observed at the IS, however a dispersed signal could
also be seen (Fig. 2C). SAR T cells also showed gran-
zyme B accumulation and degranulation at the IS,
demonstrating formation of a mature and functional IS
(Fig. 2C).
Modular, selective and reversible activation of SAR
T cells and their applied safety switches
Due to the antigen heterogeneity in AML, and because of
toxicities associated with the targeting of myeloid lineage
antigens, cell therapy approaches need to be modular and
controllable [35, 36]. To show selectivity advantages of the
SAR platform over BiTE, SAR T cells were serially titrated
in a peripheral blood mononuclear cell (PBMC) mix, then
cocultured with target cells and either a pan-T cell-targeting
molecule (anti-CD3–anti-CD33) or a SAR-specific one
(anti-E3–anti-CD33). The selective activation of SAR
T cells was evident when the SAR–PBMC mix was
cocultured with an anti-E3–anti-CD33 molecule, as IFN-γ
levels decreased with lower concentrations of SAR T cells
in the mix (Fig. 3A). This titrated T cell activation effect
was lost when the anti-CD3–anti-CD33 molecule was
employed at equivalent total cell numbers. Furthermore, the
anti-E3–anti-CD33 construct did not mediate any T cell
activation when incubated with a pure PBMC mix devoid of
SAR T cells, whereas the anti-CD3–anti-CD33 molecule
was non-selective in activating CD3+ T cells in the PBMC
mix, as expected (Fig. 3A).
An intrinsic safety switch of the SAR platform is that the
activity of SAR T cells is strictly dependent on the presence
of the taFv construct. Contrary to CAR T cells, the activity
of which is irreversible in the presence of the target antigen,
SAR T cell activity should quickly dissipate with clearance
of the taFv. Indeed, we found that, following cocultures
with MV4-11 tumor cells, SAR T cell activity was rever-
sible over time in the absence of taFv redosing, unlike
human anti-CD33 CAR T cells. Importantly, repeated
dosing of the taFv molecule could maintain SAR activity at
comparable levels to that of the CAR (Fig. 3B). This data
indicates that engineering the half-life of the taFv molecule
would enable control over SAR activity.
The relatively short half-life of the taFv molecule should
also enable modularity of the platform, i.e., the sequential
targeting of multiple antigen types that would allow for more
refined patient-specific tailoring of the treatment. Modularity
was demonstrated when the same SAR T cells were redirected
toward AML cells expressing multiple targets. SAR T cells
were cocultured with CD33+ CD123+ THP-1 cells. Through
the addition, exchange or depletion of anti-E3–anti-CD33 or
anti-E3–anti-CD123-targeting molecules we could show
modularity by sequentially redirecting SAR T cells toward
different AML targets (Fig. 3C and Supplementary Fig. 3A).
Overall, this approach has the potential to target a mul-
titude of AML-associated antigens with a level of flexibility
and controllability that is superior to that of CAR T cells.
These advantages together with the aforementioned safety
facets make this platform a promising modality for the
targeting of myeloid lineage antigens.
SAR–taFv combination can mediate specific
cytotoxicity against patient-derived AML blasts and
leukemic stem cells
To further translate the potential of our approach, we assessed
SAR T cell activity against patient-derived AML blasts. A
long-term coculture assay system was utilized to evaluate SAR
T cell-mediated cytotoxicity over time. AML blasts were
specifically targeted by SAR T cells in the presence of the
anti-E3–anti-CD33 molecule, whereas control T cell and taFv
combinations were not (Fig. 4A, B and Supplementary
Fig. 3B, C). We applied a similar setup to test the efficacy of
the approach in an autologous AML patient setting. We could
successfully isolate, culture and transduce patient-derived
T cells with the SAR (Supplementary Fig. 3D). Their capacity
to target their own blasts in the presence of either anti-E3-anti-
CD33 or anti-E3-anti-CD123 taFvs was demonstrated, with
similar effects to what was already shown in the allogeneic
setting (Fig. 4C). SAR T cell activity was also assessed by
expression of the markers PD-1, TIM-3, and CD69 after
3 days of coculture. In the presence of the taFv and AML
blasts, SAR T cells upregulated PD-1, TIM-3, and CD69
(Fig. 4D and Supplementary Fig. 3E). In addition, we could
show that the SAR–taFv combination could also effectively
target CD34+ CD38- LSC (Fig. 4E, F). The data obtained
supports the clinical application of the platform as it shows the
efficacy of the approach in targeting patient blasts and LSCs.
Fig. 1 SAR T cells can be bound and triggered by tandem scFvs to
induce T cell activation and proliferation. A Schematic overview of
the SAR construct as well as the modular composition of anti-E3–anti-
CD33 and anti-E3–anti-CD123 molecules and CD33 and CD123 tar-
get structures. B Transduction efficiency flow cytometry plot and SAR
expression data in T cells from healthy donors. C SAR and unt T cells
were cocultured with THP-1, PL-21, or MV4-11 tumor cells and anti-
E3–anti-CD33 molecule, with hIFN-γ readout 48 h after coculture.
D SAR and unt T cells were cocultured with THP-1 or MV4-11 tumor
cells and anti-E3–anti-CD123 molecule, with hIFN-γ readout 48 h
after coculture. E The proliferation rate of the T cells was determined
by flow cytometry analysis with surface staining for CD3, CD4, CD8,
and EGFR after coculture. F SAR and UT T cells were cocultured with
MV4-11 tumor cells at a 10:1 E:T ratio. Anti-E3–anti-CD33 taFv was
added at a concentration of 1 μg/ml. Readouts were carried out at 0, 24,
and 48 h time-points. PD-1 expression of SAR and UT CD4+ and CD8
+ T cells over time (0, 24, and 48 h) is shown. Statistical analysis was
performed with unpaired two-tailed Student’s t test. Experiments in
subfigures (B–F) show mean values ± SEM and are representative of
three independent experiments.
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30 min cocultures with αE3-αCD33
(1 μg/ml) and THP-1 tumor cells
Fig. 2 SAR T cells selectively form functional immunological
synapses to mediate efficient tumor cell lysis. A SAR and unt T cells
were cocultured with THP-1, PL-21, or MV4-11 tumor cells with anti-
E3–anti-CD33. Following coculture, the BioGlo Luciferase assay was
used to calculate the percentage of cells lysed—values shown were
normalized to the AML only control condition which was taken as 0 %
lysis. B SAR or unt T cells were cocultured with THP-1 tumor cells in
a V-well plate before transfer to a poly-L-lysine-coated slide. Cells
were allowed to adhere for 30 min before fixation and permeabiliza-
tion. The percentage of T cells conjugated with tumor cells was
quantified, as well as the percentage of those conjugates with a
polarized MTOC. C Double Immunofluorescence labeling was carried
out to characterize the polarization of the MTOC, Granzyme B, LFA-1
and F-actin at the SAR T cell IS. For statistical analysis the unpaired
two-tailed Student’s t test was used. Experiments in subfigures (A and
B) show mean values ± SEM and are representative of at least three
independent experiments. Subfigure (D) is representative of three
independent experiments. Leica TCS SP5 confocal system with a HCX
PL APO CS 63x/1.4 oil objective was used for image acquisition on
Leica application suite v2.7.3.9723. Tumor cells were GFP positive.
Fluorochromes used: MTOC (AF594) Granzyme B (AF647); F-actin
(AF647); LFA-1 (AF647); Lck (AF647). For z-axis image recon-
struction (stacking) confocal sections were taken 0.2 µm apart.
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Treatment with the SAR-taFv combination can
efficiently eradicate leukemia and enhance survival
in vivo
To probe the in vivo function of the SAR–taFv combination,
we took advantage of xenograft models of leukemia by
engrafting two different AML cell-lines, THP-1-LUC-GFP
and MV4-11-LUC-GFP, into NSG mice (Fig. 5A, D). In the
MV4-11 model, mice treated with the SAR T cell and anti-
E3–anti-CD33 taFv combination experienced major responses
to the therapy, with improved tumor control in all treated
mice, and a complete response observed in two out of seven
mice, which was not seen under any of the negative control
conditions. A direct comparison against aCD33-CAR-treated
mice was also carried out in this model. While a strong
antitumoral response could also be observed in the CAR-
treated group, the mice developed severe toxicity (appeared to
be non-disease related, likely graft-versus-host disease) and
were subsequently taken out of the experiment (Fig. 5B, C).
In the THP-1 model, a strong antitumoral response was also
observed with the SAR T cell and taFv combination, with one
out of five mice clearing the disease (Fig. 5E, F).
Moreover, overall survival was significantly improved in
the SAR with anti-E3–anti-CD33 treatment group compared
to SAR with anti-E3–anti-CD19 (i.e., non-AML targeting)
treatment group in both MV4-11 (p= 0.009) and THP-1
(p= 0.010) models (Fig. 5B, F). Ex vivo phenotyping of
SAR T cells at the experimental endpoint (70 days post
transfer) revealed prolonged persistence in the treated mice
of the THP-1 model. These SAR+ T cells predominantly
possessed an effector memory phenotype. CD25 and
CD69 staining revealed a higher expression in CD4+ and
CD8+ subsets in the BM compared to the spleen, which
correlated with observed tumor burden. PD-1 staining
revealed very high expression levels in both the BM and
spleen (Supplementary Fig. 4A–D). Together these data
indicate that the SAR platform can mediate substantial
therapeutic activity in relevant AML xenograft models.
To demonstrate the modularity of the SAR-taFv combi-
nation in vivo, we treated THP-1-bearing mice with SAR
T cells plus an anti-E3-anti-CD33 or anti-E3-anti-CD123
taFv. We found that mice continuously treated with either
taFv showed comparable anti-tumoral efficacy to mice where
taFv treatment was switched after four doses, indicative that
the targeting moiety can indeed be changed without T cell
reinfusion over the course of treatment. In contrast, in mice
where taFv treatment was ceased after four doses, the disease
quickly progressed, reaching comparable levels to that of
mice that received no taFv treatment (Supplementary Fig. 5A,
B). This demonstrates the reversibility of T cell activation
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Fig. 3 Modular, selective and reversible activation of SAR T cells
and their applied safety switches. A SAR T cells were serially
titrated (1:40, 1:60, 1:80, 0:100) in a PBMC mix. Cells were then
cocultured with MV4-11 tumor cells (E:T 10:1), with either a pan-T
cell (anti-CD3–anti-CD33, 1 μg/ml) or a SAR-specific molecule (anti-
E3–anti-CD33, 1 μg/ml). B MV4-11 tumor cells were repeatedly
cocultured with SAR T cells with or without redosage of the constructs
(1 μg/ml). Anti-CD33 CAR T cells were used as a control and
cocultured with tumor cells following the same procedure (no taFv
was added) (E:T 10:1). C A modularity stress test was carried out
using anti-E3–anti-CD33 and anti-E3–anti-CD123 molecules (1 µg/
ml). SAR or unt T cells were cocultured with THP-1 tumor cells (E:T
10:1). Readouts were carried out at 24 or 48 h. At assay start, cocul-
tures received either anti-E3–anti-CD33 molecules, anti-E3–anti-
CD123 molecules, or no molecules. At 24 h, cocultures were either
redosed with the same taFv, redosed with the other taFv against a
different target, dosed for the first time with either molecule, or not
redosed after initial dosing. At each time point, supernatants were
collected and subjected to a hIFN-γ ELISA readout. For statistical
analysis, the unpaired two-tailed Student’s t test was used. Experi-
ments show mean values ± SEM and are representative of three
independent experiments.
M.-R. Benmebarek et al.
Discussion
Donor T cell alloreactivity driving the graft-versus-
leukemia effect is a major mechanism behind the curative
effect of allo-SCT, and supports the notion that T cells
are crucial effector cells in the context of AML therapy
[37, 38]. Importantly, there is strong preclinical and
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effective means of targeting and eliminating AML, includ-
ing LSCs [39].
Our studies demonstrate that SAR T cells can be redir-
ected by a SAR-specific taFv construct toward the aber-
rantly expressed AML antigens CD33 and CD123. We
could show that SAR T cells are able to specifically
recognize multiple targets on several AML cell lines,
demonstrating in vitro and in vivo efficacy. We also showed
induction of a functional synapse (MTOC polarization, F-
actin area), whereas Lck and LFA-1 organization patterns
were comparable to those reported for the IS of CAR T cells
[40]. This targeted specificity and cytolytic capacity was
furthermore demonstrated by the successful targeting of
patient-derived AML blasts and LSCs. The potent anti-
leukemic activity observed with the SAR platform, in
in vivo models and against patient-derived AML blasts, is
comparable to those observed in the preclinical testing of
AML-targeting BiTEs and CARs [30, 41, 42].
Despite its similarly broad expression on myeloid pro-
genitors and some normal B cell and activated T cell
populations, CD33 remains a valuable antigen for the tar-
geting of AML due to its overexpression on blasts in all
AML [43, 44]. Low CD33 antigen density in subsets of
patient blasts remains a caveat of targeting this antigen [17].
To tackle this, we designed the taFv molecule with a
comparably higher CD33 binding affinity, resulting in better
targeting of blasts with low CD33 surface expression. A
higher affinity for the tumor antigen also means a taFv
matrix can be formed on the surface of the AML cells, upon
which SAR T cells, with their lower affinity to the taFv, can
mediate serial tumor cell killing more efficiently [33, 45].
This design also minimizes antibody trapping in T cell-
containing tissues, such as the spleen or lymph nodes,
reducing the potential for off-target toxicity [46, 47].
To date, anti-AML CAR T cells have shown limited
efficacy in the clinic [48, 49], with on-target off-tumor
toxicity being especially problematic in the context of tar-
geting CD33 [50, 51]. To overcome these challenges,
highly modular and controllable approaches, as well as
those that can make normal hematopoiesis resistant to tar-
geted therapy are needed. One such approach could gen-
erate hematopoietic systems unaffected by CD33-targeted
therapy [52, 53]. Our SAR platform repurposed for AML,
remains, as previously described, highly modular and con-
trollable [22]. Through the direct comparison of a pan-T cell
targeting molecule with a SAR-specific one, we could
substantiate the claim that nonengineered T cells are not
affected by the platform. This level of controllability means
the SAR platform distinguishes between two T cell popu-
lations in the patient (engineered and nonengineered),
which can be carefully selected and tailored. Once the T cell
arm of the therapy is adoptively transferred, the redirection
and subsequent activation of SAR T cells is completely
dependent on the taFv. Clearance of the taFv, in the event of
toxicity or on-target-off-tumor activity, would reverse SAR
T cell activity. Further or sequential targeting of the AML
through the redirection of pre-existing SAR T cells could
then be achieved through the introduction of a new taFv
with a different AML specificity. In the event of target
downregulation as an escape mechanism following treat-
ment (the most prevalent resistance mechanism observed
following blinatumomab treatment in ALL patients), plat-
form modularity would again be advantageous. Further-
more, an additional safety layer is ensured by the unique
expression of EGFRvIII on SAR T cells (otherwise only
expressed on pathologic tissues, such as gliomas), thus
depletion with cetuximab as another safety switch is pos-
sible if required [22]. Taken together, the SAR platform
aligns the advantages of antibody therapy (controllable
dosing and reversibility) with that of adoptive T cell therapy
(potent anti-tumoral effectors).
Many approaches have emerged attempting to make
CAR T cells more modular and controllable. These
Fig. 4 SAR–taFv combination can activate SAR T cells to mediate
specific cytotoxicity against patient AML blasts and LSCs.
A Patient-derived AML blasts targeted by SAR T cells (E:T 1:1) and
an anti-E3–anti-CD33 taFv (1 µg/ml), or with controls (SAR T cells
and patient blasts, unt T cells with anti-E3–anti-CD33 and patient
blasts, unt T cells and patient blasts). In a long-term coculture assay
set-up, flow cytometry-based readouts were taken after 3, 7, and
10 days. Cells were stained for CD2 and CD33, to differentiate the
T cells and AML blasts respectively. B The percentage lysis of patient-
derived AML blasts (n= 11) by SAR T cells and taFv was calculated
as a ratio and compared to unt cells and AML blasts. C Patient-derived
AML blasts targeted by autologous SAR T cells (E:T 1:1) and either
an anti-E3–anti-CD33 taFv (1 µg/ml) or an anti-E3–anti-CD123 taFv
(1 µg/ml), or with controls (SAR T cells and patient blasts, unt T cells
with either taFv and patient blasts, unt T cells and patient blasts). In a
coculture assay set-up, flow cytometry-based readouts were taken after
3 days. Cells were stained for CD2 and CD33, to differentiate the
T cells and AML blasts respectively. D Following coculture (at day 3),
T cells were also stained for CD69, PD-1 and TIM-3. E Short-term
coculture (18 h) assays were set-up between 5 × 105 patient blasts and
SAR T cells (E:T 1:1) and an anti-E3–anti-CD33 (1 µg/ml) or an anti-
E3–anti-CD123 (1 µg/ml) molecule, or with controls (SAR T cells
only, anti-E3–anti-CD33 and anti-E3–anti-CD123 molecules only,
patient blasts only, unt T cells with anti-E3–anti-CD33 and anti-
E3–anti-CD123 molecules, unt T cells with AML blasts). To show
efficiency of LSC killing, blasts were stained for CD45, CD34, and
CD38, and lysis of the CD34+CD38- LSC population was quantified
as a ratio over unt T cells with patient blasts as a control condition.
F Representative flow cytometry plots from coculture experiment
described in subfigure (E). For statistical analysis, the paired two-
tailed Student’s t test was used. Experiments show mean values ±
SEM. Experiments in subfigures (A, B, and D) are representative of six
independent long term coculture (LTC) experiments, with multiple
patients used per LTC. Experiments in subfigure (C) are representative
of two independent coculture experiments, with two to three patients
used per coculture. Experiments in subfigure E are representative of
four independent short term coculture experiments. Patient information
for each experiment is listed in supplementary Table 2. CD33 and
CD123 patient expression data is depicted in supplementary Fig. 4.
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include but are not restricted to the SUPRA CAR (with
tunable availability and affinity) [54], CAR T cells using
the synNotch receptor (that can induce transcription of
CAR expression to target a second antigen) [55], bispe-
cific CARs (can target two tumor antigens inter-
changeably) [56] and suicide CAR T cells (such as those
using the inducible caspase 9 system, whereby small
molecules can activate apoptosis independent of CAR
activation) [57]. The SUPRA CAR has the potential to
improve the broader applicability and modularity of CAR
T cells. The published data however does not show dur-
able in vivo efficacy, while the controllability data (in
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Furthermore, its applicability and tailoring toward spe-
cific disease settings, such as AML, is yet to be shown [54].
Bispecific CAR T cells are already in clinical testing (anti-
CLL-1–anti-CD33; NCT03795779), though given the
interpatient LSC diversity, it is unlikely that any two-
antigen combination would suffice in eradicating disease
across patient cohorts. By comparison, our platform gives
more freedom in tailoring a patient-specific combination
therapy. As mentioned, the AML setting stands to benefit
from improved target selectivity. Application of the syn-
Notch CAR system could improve safety and reduce
myeloid toxicity [55]. Despite this, the system still lacks
modularity, an important feature for improved targeting of
heterogeneous leukemic stem cell populations in AML. A
big challenge in the CAR system is autonomous signaling
[58]. This is in contrast to the SAR-taFv platform which
provides a functionally inert molecule only triggered by the
addition of a specific taFv but not by any other known
molecule in the body.
Furthermore, many of the modular CAR approaches
(such as switchable CAR T cells) rely on the introduction of
a neoepitope for selective targeting [59], which comes with
immunogenicity issues driving either anti-drug immune
responses and dampening activity or potentially triggering
toxicities or all of it. SAR T cells and their triggering taFv
are fully human or humanizable proteins which markedly
reduces immunogenicity risks. Despite the appeal, suicide
systems in CARs is a rather brute approach that eliminates
all effector cells and requires additional genetic modifica-
tions. Importantly, the ability to deplete CAR T cells in the
event of toxicities remains to be demonstrated clinically.
These approaches have been comprehensively reviewed by
Darowski et al. [60].
Perhaps the greatest challenge hindering the success of
adoptive T cell therapy in AML is target specificity, which
results from disease heterogeneity and diverse antigen
expression on LSCs. A recent AML proteomic and tran-
scriptomic study revealed a series of differentially expressed
AML-specific antigens, out of which came the rationale that
systematic therapeutic combinations would be ideal in the
context of AML therapy [18]. This approach was given
clinical relevance after a coexpression profile of LSC mar-
kers was described for AML patients [17]. The authors
found CD33, CD123, CLL1, TIM3, and CD244 to be
ubiquitously expressed on AML cells both at diagnosis and
relapse stages, and further stressed the benefits of a dual
targeting approach for AML. Thus, despite CD33 being
expressed on the vast majority of LSCs, the importance of a
modular approach with the capacity to simultaneously, or,
in the event of antigen escape (or clonal heterogeneity),
sequentially target other AML-specific antigens is clear, and
is further evidenced by previous work [2, 61].
A strength of our platform—its modularity, stands to
benefit from the significant research that has already been
carried out on many AML targets as stand-alone targeted
therapies [16, 46, 62]. Thus, the repurposing of this
knowledge might be a fast and effective method to accel-
erate the pre-clinical development of the approach. As
specific taFv molecules can be tailored individually, the
potential for combinatorial approaches will only be limited
by the testing and approval of the separate molecules. The
SAR platform still stands to benefit from certain optimiza-
tions. Amongst these is the modulation of SAR surface
expression, an approach that has been successfully applied
to the CAR T cell setting [63]. In addition, while advanta-
geous, the short half-life of the taFv will likely require
regular infusions, which could present hurdles in the form
of practicality and cost.
Collectively, we could comprehensively demonstrate that
AML-specific taFvs can be effectively used to target AML
in a controllable manner. While further development and
more extensive testing are required before its application in
a clinical setting, the SAR platform undoubtedly offers new
solutions to the ever-challenging AML disease setting.
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